nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CYP2C8—Tazarotene—psoriasis	0.0821	0.154	CbGbCtD
Paroxetine—CYP2B6—Cholecalciferol—psoriasis	0.0463	0.0867	CbGbCtD
Paroxetine—CYP2D6—Hydroxyurea—psoriasis	0.0369	0.0691	CbGbCtD
Paroxetine—CYP2C8—Cholecalciferol—psoriasis	0.0351	0.0657	CbGbCtD
Paroxetine—CYP2C8—Mycophenolate mofetil—psoriasis	0.0304	0.0569	CbGbCtD
Paroxetine—CYP2C9—Cholecalciferol—psoriasis	0.0245	0.0458	CbGbCtD
Paroxetine—CYP2C8—Hydrocortisone—psoriasis	0.0244	0.0457	CbGbCtD
Paroxetine—CYP2C8—Cyclosporine—psoriasis	0.023	0.0431	CbGbCtD
Paroxetine—CYP2D6—Cholecalciferol—psoriasis	0.0224	0.0419	CbGbCtD
Paroxetine—ABCB1—Mycophenolate mofetil—psoriasis	0.0206	0.0385	CbGbCtD
Paroxetine—CYP2B6—Dexamethasone—psoriasis	0.02	0.0375	CbGbCtD
Paroxetine—ABCB1—Betamethasone—psoriasis	0.0177	0.0331	CbGbCtD
Paroxetine—ABCB1—Prednisolone—psoriasis	0.0174	0.0326	CbGbCtD
Paroxetine—ABCB1—Hydrocortisone—psoriasis	0.0165	0.0309	CbGbCtD
Paroxetine—ABCB1—Prednisone—psoriasis	0.0165	0.0308	CbGbCtD
Paroxetine—CYP2C9—Cyclosporine—psoriasis	0.0161	0.0301	CbGbCtD
Paroxetine—ABCB1—Cyclosporine—psoriasis	0.0156	0.0292	CbGbCtD
Paroxetine—CYP2C8—Dexamethasone—psoriasis	0.0152	0.0284	CbGbCtD
Paroxetine—CYP2D6—Cyclosporine—psoriasis	0.0147	0.0275	CbGbCtD
Paroxetine—CYP2C9—Dexamethasone—psoriasis	0.0106	0.0198	CbGbCtD
Paroxetine—ABCB1—Dexamethasone—psoriasis	0.0103	0.0192	CbGbCtD
Paroxetine—CYP2D6—Dexamethasone—psoriasis	0.00968	0.0181	CbGbCtD
Paroxetine—ABCB1—Methotrexate—psoriasis	0.00825	0.0155	CbGbCtD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—NFKB1—psoriasis	6.91e-05	0.00144	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—CP—psoriasis	6.56e-05	0.00136	CbGpPWpGaD
Paroxetine—TACR1—GPCR ligand binding—CXCL8—psoriasis	6.52e-05	0.00135	CbGpPWpGaD
Paroxetine—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	6.49e-05	0.00135	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HCAR2—psoriasis	6.47e-05	0.00134	CbGpPWpGaD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—psoriasis	6.27e-05	0.0013	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—CCL20—psoriasis	6.26e-05	0.0013	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—CARM1—psoriasis	6.26e-05	0.0013	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HCAR2—psoriasis	6.19e-05	0.00129	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—CCL20—psoriasis	6e-05	0.00125	CbGpPWpGaD
Paroxetine—SLC6A4—Circadian rythm related genes—JUN—psoriasis	5.86e-05	0.00122	CbGpPWpGaD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	5.84e-05	0.00121	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—CCL20—psoriasis	5.69e-05	0.00118	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—LEP—psoriasis	5.68e-05	0.00118	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TAGAP—psoriasis	5.61e-05	0.00116	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—NDUFA5—psoriasis	5.53e-05	0.00115	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—CCL20—psoriasis	5.45e-05	0.00113	CbGpPWpGaD
Paroxetine—ABCB1—Allograft Rejection—IFNG—psoriasis	5.42e-05	0.00113	CbGpPWpGaD
Paroxetine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	5.41e-05	0.00112	CbGpPWpGaD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—psoriasis	5.38e-05	0.00112	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TAGAP—psoriasis	5.37e-05	0.00112	CbGpPWpGaD
Paroxetine—Discomfort—Dexamethasone—psoriasis	5.35e-05	0.000128	CcSEcCtD
Paroxetine—Discomfort—Betamethasone—psoriasis	5.35e-05	0.000128	CcSEcCtD
Paroxetine—Dyspepsia—Hydrocortisone—psoriasis	5.35e-05	0.000128	CcSEcCtD
Paroxetine—Haemoglobin—Methotrexate—psoriasis	5.35e-05	0.000128	CcSEcCtD
Paroxetine—Rash—Mycophenolic acid—psoriasis	5.33e-05	0.000128	CcSEcCtD
Paroxetine—Dermatitis—Mycophenolic acid—psoriasis	5.33e-05	0.000128	CcSEcCtD
Paroxetine—Pain—Prednisolone—psoriasis	5.32e-05	0.000127	CcSEcCtD
Paroxetine—Hepatitis—Methotrexate—psoriasis	5.32e-05	0.000127	CcSEcCtD
Paroxetine—Haemorrhage—Methotrexate—psoriasis	5.32e-05	0.000127	CcSEcCtD
Paroxetine—Urticaria—Mycophenolate mofetil—psoriasis	5.3e-05	0.000127	CcSEcCtD
Paroxetine—Headache—Mycophenolic acid—psoriasis	5.3e-05	0.000127	CcSEcCtD
Paroxetine—CHRM1—Circadian rythm related genes—NOS2—psoriasis	5.3e-05	0.0011	CbGpPWpGaD
Paroxetine—Decreased appetite—Hydrocortisone—psoriasis	5.28e-05	0.000127	CcSEcCtD
Paroxetine—Pharyngitis—Methotrexate—psoriasis	5.28e-05	0.000126	CcSEcCtD
Paroxetine—Abdominal pain—Mycophenolate mofetil—psoriasis	5.28e-05	0.000126	CcSEcCtD
Paroxetine—Body temperature increased—Mycophenolate mofetil—psoriasis	5.28e-05	0.000126	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Hydrocortisone—psoriasis	5.25e-05	0.000126	CcSEcCtD
Paroxetine—Fatigue—Hydrocortisone—psoriasis	5.24e-05	0.000125	CcSEcCtD
Paroxetine—Vision blurred—Prednisone—psoriasis	5.22e-05	0.000125	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Triamcinolone—psoriasis	5.22e-05	0.000125	CcSEcCtD
Paroxetine—Pain—Hydrocortisone—psoriasis	5.2e-05	0.000124	CcSEcCtD
Paroxetine—Oedema—Dexamethasone—psoriasis	5.19e-05	0.000124	CcSEcCtD
Paroxetine—Oedema—Betamethasone—psoriasis	5.19e-05	0.000124	CcSEcCtD
Paroxetine—Anaphylactic shock—Betamethasone—psoriasis	5.19e-05	0.000124	CcSEcCtD
Paroxetine—Anaphylactic shock—Dexamethasone—psoriasis	5.19e-05	0.000124	CcSEcCtD
Paroxetine—Insomnia—Triamcinolone—psoriasis	5.18e-05	0.000124	CcSEcCtD
Paroxetine—Infection—Betamethasone—psoriasis	5.16e-05	0.000124	CcSEcCtD
Paroxetine—Infection—Dexamethasone—psoriasis	5.16e-05	0.000124	CcSEcCtD
Paroxetine—Ill-defined disorder—Prednisone—psoriasis	5.14e-05	0.000123	CcSEcCtD
Paroxetine—Paraesthesia—Triamcinolone—psoriasis	5.14e-05	0.000123	CcSEcCtD
Paroxetine—Feeling abnormal—Prednisolone—psoriasis	5.13e-05	0.000123	CcSEcCtD
Paroxetine—Visual impairment—Methotrexate—psoriasis	5.13e-05	0.000123	CcSEcCtD
Paroxetine—Anaemia—Prednisone—psoriasis	5.12e-05	0.000123	CcSEcCtD
Paroxetine—Shock—Dexamethasone—psoriasis	5.11e-05	0.000122	CcSEcCtD
Paroxetine—Shock—Betamethasone—psoriasis	5.11e-05	0.000122	CcSEcCtD
Paroxetine—Dyspnoea—Triamcinolone—psoriasis	5.1e-05	0.000122	CcSEcCtD
Paroxetine—Nervous system disorder—Betamethasone—psoriasis	5.09e-05	0.000122	CcSEcCtD
Paroxetine—Nervous system disorder—Dexamethasone—psoriasis	5.09e-05	0.000122	CcSEcCtD
Paroxetine—Agitation—Prednisone—psoriasis	5.09e-05	0.000122	CcSEcCtD
Paroxetine—Thrombocytopenia—Betamethasone—psoriasis	5.09e-05	0.000122	CcSEcCtD
Paroxetine—Thrombocytopenia—Dexamethasone—psoriasis	5.09e-05	0.000122	CcSEcCtD
Paroxetine—Tachycardia—Dexamethasone—psoriasis	5.07e-05	0.000121	CcSEcCtD
Paroxetine—Tachycardia—Betamethasone—psoriasis	5.07e-05	0.000121	CcSEcCtD
Paroxetine—Angioedema—Prednisone—psoriasis	5.06e-05	0.000121	CcSEcCtD
Paroxetine—ABCB1—Allograft Rejection—CXCL8—psoriasis	5.04e-05	0.00105	CbGpPWpGaD
Paroxetine—Hypersensitivity—Cyclosporine—psoriasis	5.04e-05	0.000121	CcSEcCtD
Paroxetine—Dyspepsia—Triamcinolone—psoriasis	5.04e-05	0.000121	CcSEcCtD
Paroxetine—Erythema multiforme—Methotrexate—psoriasis	5.03e-05	0.00012	CcSEcCtD
Paroxetine—Nausea—Mycophenolic acid—psoriasis	5.02e-05	0.00012	CcSEcCtD
Paroxetine—Hyperhidrosis—Dexamethasone—psoriasis	5.02e-05	0.00012	CcSEcCtD
Paroxetine—Hyperhidrosis—Betamethasone—psoriasis	5.02e-05	0.00012	CcSEcCtD
Paroxetine—Feeling abnormal—Hydrocortisone—psoriasis	5.01e-05	0.00012	CcSEcCtD
Paroxetine—Malaise—Prednisone—psoriasis	5e-05	0.00012	CcSEcCtD
Paroxetine—Vertigo—Prednisone—psoriasis	4.98e-05	0.000119	CcSEcCtD
Paroxetine—Eye disorder—Methotrexate—psoriasis	4.97e-05	0.000119	CcSEcCtD
Paroxetine—Gastrointestinal pain—Hydrocortisone—psoriasis	4.97e-05	0.000119	CcSEcCtD
Paroxetine—Syncope—Prednisone—psoriasis	4.97e-05	0.000119	CcSEcCtD
Paroxetine—Tinnitus—Methotrexate—psoriasis	4.96e-05	0.000119	CcSEcCtD
Paroxetine—CHRM1—Circadian rythm related genes—PPARG—psoriasis	4.95e-05	0.00103	CbGpPWpGaD
Paroxetine—Urticaria—Prednisolone—psoriasis	4.95e-05	0.000118	CcSEcCtD
Paroxetine—CHRM4—G alpha (i) signalling events—CXCL8—psoriasis	4.94e-05	0.00103	CbGpPWpGaD
Paroxetine—Cardiac disorder—Methotrexate—psoriasis	4.94e-05	0.000118	CcSEcCtD
Paroxetine—Fatigue—Triamcinolone—psoriasis	4.94e-05	0.000118	CcSEcCtD
Paroxetine—Hypersensitivity—Mycophenolate mofetil—psoriasis	4.92e-05	0.000118	CcSEcCtD
Paroxetine—Asthenia—Cyclosporine—psoriasis	4.91e-05	0.000117	CcSEcCtD
Paroxetine—Pain—Triamcinolone—psoriasis	4.9e-05	0.000117	CcSEcCtD
Paroxetine—Loss of consciousness—Prednisone—psoriasis	4.87e-05	0.000117	CcSEcCtD
Paroxetine—Hypotension—Betamethasone—psoriasis	4.85e-05	0.000116	CcSEcCtD
Paroxetine—Hypotension—Dexamethasone—psoriasis	4.85e-05	0.000116	CcSEcCtD
Paroxetine—Pruritus—Cyclosporine—psoriasis	4.84e-05	0.000116	CcSEcCtD
Paroxetine—Urticaria—Hydrocortisone—psoriasis	4.83e-05	0.000116	CcSEcCtD
Paroxetine—Angiopathy—Methotrexate—psoriasis	4.83e-05	0.000116	CcSEcCtD
Paroxetine—Immune system disorder—Methotrexate—psoriasis	4.81e-05	0.000115	CcSEcCtD
Paroxetine—Abdominal pain—Hydrocortisone—psoriasis	4.81e-05	0.000115	CcSEcCtD
Paroxetine—Body temperature increased—Hydrocortisone—psoriasis	4.81e-05	0.000115	CcSEcCtD
Paroxetine—Convulsion—Prednisone—psoriasis	4.8e-05	0.000115	CcSEcCtD
Paroxetine—Mediastinal disorder—Methotrexate—psoriasis	4.8e-05	0.000115	CcSEcCtD
Paroxetine—Asthenia—Mycophenolate mofetil—psoriasis	4.79e-05	0.000115	CcSEcCtD
Paroxetine—Hypertension—Prednisone—psoriasis	4.79e-05	0.000115	CcSEcCtD
Paroxetine—Chills—Methotrexate—psoriasis	4.77e-05	0.000114	CcSEcCtD
Paroxetine—CYP2B6—Metabolism—NDUFA5—psoriasis	4.76e-05	0.000988	CbGpPWpGaD
Paroxetine—Musculoskeletal discomfort—Dexamethasone—psoriasis	4.73e-05	0.000113	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Betamethasone—psoriasis	4.73e-05	0.000113	CcSEcCtD
Paroxetine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.73e-05	0.000982	CbGpPWpGaD
Paroxetine—Pruritus—Mycophenolate mofetil—psoriasis	4.72e-05	0.000113	CcSEcCtD
Paroxetine—Arthralgia—Prednisone—psoriasis	4.72e-05	0.000113	CcSEcCtD
Paroxetine—Myalgia—Prednisone—psoriasis	4.72e-05	0.000113	CcSEcCtD
Paroxetine—Feeling abnormal—Triamcinolone—psoriasis	4.72e-05	0.000113	CcSEcCtD
Paroxetine—Anxiety—Prednisone—psoriasis	4.7e-05	0.000113	CcSEcCtD
Paroxetine—Alopecia—Methotrexate—psoriasis	4.7e-05	0.000113	CcSEcCtD
Paroxetine—CHRM3—Metabolism—CYP2S1—psoriasis	4.7e-05	0.000977	CbGpPWpGaD
Paroxetine—Insomnia—Dexamethasone—psoriasis	4.7e-05	0.000112	CcSEcCtD
Paroxetine—Insomnia—Betamethasone—psoriasis	4.7e-05	0.000112	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	4.69e-05	0.000112	CcSEcCtD
Paroxetine—Diarrhoea—Cyclosporine—psoriasis	4.68e-05	0.000112	CcSEcCtD
Paroxetine—Paraesthesia—Betamethasone—psoriasis	4.66e-05	0.000112	CcSEcCtD
Paroxetine—Paraesthesia—Dexamethasone—psoriasis	4.66e-05	0.000112	CcSEcCtD
Paroxetine—Discomfort—Prednisone—psoriasis	4.66e-05	0.000112	CcSEcCtD
Paroxetine—Mental disorder—Methotrexate—psoriasis	4.66e-05	0.000112	CcSEcCtD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—CXCL8—psoriasis	4.65e-05	0.000966	CbGpPWpGaD
Paroxetine—Erythema—Methotrexate—psoriasis	4.63e-05	0.000111	CcSEcCtD
Paroxetine—Malnutrition—Methotrexate—psoriasis	4.63e-05	0.000111	CcSEcCtD
Paroxetine—Hypersensitivity—Prednisolone—psoriasis	4.59e-05	0.00011	CcSEcCtD
Paroxetine—Dyspepsia—Betamethasone—psoriasis	4.57e-05	0.000109	CcSEcCtD
Paroxetine—Dyspepsia—Dexamethasone—psoriasis	4.57e-05	0.000109	CcSEcCtD
Paroxetine—Diarrhoea—Mycophenolate mofetil—psoriasis	4.57e-05	0.000109	CcSEcCtD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—CXCL8—psoriasis	4.57e-05	0.000948	CbGpPWpGaD
Paroxetine—Urticaria—Triamcinolone—psoriasis	4.55e-05	0.000109	CcSEcCtD
Paroxetine—Dysgeusia—Methotrexate—psoriasis	4.54e-05	0.000109	CcSEcCtD
Paroxetine—Body temperature increased—Triamcinolone—psoriasis	4.53e-05	0.000108	CcSEcCtD
Paroxetine—Dizziness—Cyclosporine—psoriasis	4.52e-05	0.000108	CcSEcCtD
Paroxetine—Anaphylactic shock—Prednisone—psoriasis	4.52e-05	0.000108	CcSEcCtD
Paroxetine—Oedema—Prednisone—psoriasis	4.52e-05	0.000108	CcSEcCtD
Paroxetine—Decreased appetite—Betamethasone—psoriasis	4.52e-05	0.000108	CcSEcCtD
Paroxetine—Decreased appetite—Dexamethasone—psoriasis	4.52e-05	0.000108	CcSEcCtD
Paroxetine—Infection—Prednisone—psoriasis	4.49e-05	0.000108	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Betamethasone—psoriasis	4.48e-05	0.000107	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Dexamethasone—psoriasis	4.48e-05	0.000107	CcSEcCtD
Paroxetine—Back pain—Methotrexate—psoriasis	4.48e-05	0.000107	CcSEcCtD
Paroxetine—Hypersensitivity—Hydrocortisone—psoriasis	4.48e-05	0.000107	CcSEcCtD
Paroxetine—Fatigue—Betamethasone—psoriasis	4.48e-05	0.000107	CcSEcCtD
Paroxetine—Fatigue—Dexamethasone—psoriasis	4.48e-05	0.000107	CcSEcCtD
Paroxetine—Shock—Prednisone—psoriasis	4.45e-05	0.000107	CcSEcCtD
Paroxetine—Pain—Dexamethasone—psoriasis	4.44e-05	0.000106	CcSEcCtD
Paroxetine—Pain—Betamethasone—psoriasis	4.44e-05	0.000106	CcSEcCtD
Paroxetine—Nervous system disorder—Prednisone—psoriasis	4.44e-05	0.000106	CcSEcCtD
Paroxetine—Tachycardia—Prednisone—psoriasis	4.41e-05	0.000106	CcSEcCtD
Paroxetine—Dizziness—Mycophenolate mofetil—psoriasis	4.41e-05	0.000106	CcSEcCtD
Paroxetine—Skin disorder—Prednisone—psoriasis	4.39e-05	0.000105	CcSEcCtD
Paroxetine—HTR2A—Signaling Pathways—HCAR2—psoriasis	4.38e-05	0.000911	CbGpPWpGaD
Paroxetine—Hyperhidrosis—Prednisone—psoriasis	4.37e-05	0.000105	CcSEcCtD
Paroxetine—Vision blurred—Methotrexate—psoriasis	4.37e-05	0.000105	CcSEcCtD
Paroxetine—Asthenia—Hydrocortisone—psoriasis	4.36e-05	0.000104	CcSEcCtD
Paroxetine—CHRM1—Signaling Pathways—HCAR2—psoriasis	4.36e-05	0.000906	CbGpPWpGaD
Paroxetine—Vomiting—Cyclosporine—psoriasis	4.35e-05	0.000104	CcSEcCtD
Paroxetine—CHRM3—Signaling Pathways—HCAR2—psoriasis	4.35e-05	0.000903	CbGpPWpGaD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—psoriasis	4.34e-05	0.000901	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—JUN—psoriasis	4.32e-05	0.000898	CbGpPWpGaD
Paroxetine—Rash—Cyclosporine—psoriasis	4.31e-05	0.000103	CcSEcCtD
Paroxetine—Dermatitis—Cyclosporine—psoriasis	4.31e-05	0.000103	CcSEcCtD
Paroxetine—CHRM2—Signaling Pathways—HCAR2—psoriasis	4.3e-05	0.000894	CbGpPWpGaD
Paroxetine—Pruritus—Hydrocortisone—psoriasis	4.3e-05	0.000103	CcSEcCtD
Paroxetine—Ill-defined disorder—Methotrexate—psoriasis	4.3e-05	0.000103	CcSEcCtD
Paroxetine—Headache—Cyclosporine—psoriasis	4.29e-05	0.000103	CcSEcCtD
Paroxetine—Anaemia—Methotrexate—psoriasis	4.28e-05	0.000102	CcSEcCtD
Paroxetine—Feeling abnormal—Dexamethasone—psoriasis	4.28e-05	0.000102	CcSEcCtD
Paroxetine—Feeling abnormal—Betamethasone—psoriasis	4.28e-05	0.000102	CcSEcCtD
Paroxetine—Gastrointestinal pain—Betamethasone—psoriasis	4.25e-05	0.000102	CcSEcCtD
Paroxetine—Gastrointestinal pain—Dexamethasone—psoriasis	4.25e-05	0.000102	CcSEcCtD
Paroxetine—HTR2A—GPCR downstream signaling—CCL20—psoriasis	4.25e-05	0.000882	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—JUN—psoriasis	4.24e-05	0.000882	CbGpPWpGaD
Paroxetine—Vomiting—Mycophenolate mofetil—psoriasis	4.24e-05	0.000102	CcSEcCtD
Paroxetine—CHRM1—GPCR downstream signaling—CCL20—psoriasis	4.22e-05	0.000877	CbGpPWpGaD
Paroxetine—Hypersensitivity—Triamcinolone—psoriasis	4.22e-05	0.000101	CcSEcCtD
Paroxetine—CHRM3—GPCR downstream signaling—CCL20—psoriasis	4.21e-05	0.000874	CbGpPWpGaD
Paroxetine—Rash—Mycophenolate mofetil—psoriasis	4.21e-05	0.000101	CcSEcCtD
Paroxetine—Dermatitis—Mycophenolate mofetil—psoriasis	4.2e-05	0.000101	CcSEcCtD
Paroxetine—Headache—Mycophenolate mofetil—psoriasis	4.18e-05	0.0001	CcSEcCtD
Paroxetine—Malaise—Methotrexate—psoriasis	4.18e-05	0.0001	CcSEcCtD
Paroxetine—CHRM2—GPCR downstream signaling—CCL20—psoriasis	4.17e-05	0.000866	CbGpPWpGaD
Paroxetine—Vertigo—Methotrexate—psoriasis	4.16e-05	9.96e-05	CcSEcCtD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—NFKB1—psoriasis	4.16e-05	0.000864	CbGpPWpGaD
Paroxetine—Diarrhoea—Hydrocortisone—psoriasis	4.16e-05	9.96e-05	CcSEcCtD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	4.15e-05	0.000863	CbGpPWpGaD
Paroxetine—Leukopenia—Methotrexate—psoriasis	4.15e-05	9.93e-05	CcSEcCtD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	4.13e-05	0.000858	CbGpPWpGaD
Paroxetine—Urticaria—Betamethasone—psoriasis	4.13e-05	9.88e-05	CcSEcCtD
Paroxetine—Urticaria—Dexamethasone—psoriasis	4.13e-05	9.88e-05	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Prednisone—psoriasis	4.12e-05	9.87e-05	CcSEcCtD
Paroxetine—Dizziness—Prednisolone—psoriasis	4.12e-05	9.85e-05	CcSEcCtD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	4.11e-05	0.000854	CbGpPWpGaD
Paroxetine—Asthenia—Triamcinolone—psoriasis	4.11e-05	9.83e-05	CcSEcCtD
Paroxetine—Body temperature increased—Betamethasone—psoriasis	4.11e-05	9.83e-05	CcSEcCtD
Paroxetine—Body temperature increased—Dexamethasone—psoriasis	4.11e-05	9.83e-05	CcSEcCtD
Paroxetine—Abdominal pain—Dexamethasone—psoriasis	4.11e-05	9.83e-05	CcSEcCtD
Paroxetine—Abdominal pain—Betamethasone—psoriasis	4.11e-05	9.83e-05	CcSEcCtD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	4.1e-05	0.000851	CbGpPWpGaD
Paroxetine—ABCB1—Allograft Rejection—VEGFA—psoriasis	4.09e-05	0.000851	CbGpPWpGaD
Paroxetine—Insomnia—Prednisone—psoriasis	4.09e-05	9.79e-05	CcSEcCtD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—NFKB1—psoriasis	4.09e-05	0.000849	CbGpPWpGaD
Paroxetine—Nausea—Cyclosporine—psoriasis	4.06e-05	9.73e-05	CcSEcCtD
Paroxetine—Paraesthesia—Prednisone—psoriasis	4.06e-05	9.72e-05	CcSEcCtD
Paroxetine—Pruritus—Triamcinolone—psoriasis	4.05e-05	9.7e-05	CcSEcCtD
Paroxetine—CYP2B6—Metabolism—CYP2S1—psoriasis	4.04e-05	0.00084	CbGpPWpGaD
Paroxetine—Cough—Methotrexate—psoriasis	4.04e-05	9.68e-05	CcSEcCtD
Paroxetine—TACR1—Signaling Pathways—SOCS1—psoriasis	4.03e-05	0.000837	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—NDUFA5—psoriasis	4.03e-05	0.000837	CbGpPWpGaD
Paroxetine—Dizziness—Hydrocortisone—psoriasis	4.02e-05	9.62e-05	CcSEcCtD
Paroxetine—Convulsion—Methotrexate—psoriasis	4.01e-05	9.61e-05	CcSEcCtD
Paroxetine—Dyspepsia—Prednisone—psoriasis	3.98e-05	9.53e-05	CcSEcCtD
Paroxetine—Nausea—Mycophenolate mofetil—psoriasis	3.96e-05	9.49e-05	CcSEcCtD
Paroxetine—Myalgia—Methotrexate—psoriasis	3.94e-05	9.44e-05	CcSEcCtD
Paroxetine—Chest pain—Methotrexate—psoriasis	3.94e-05	9.44e-05	CcSEcCtD
Paroxetine—Arthralgia—Methotrexate—psoriasis	3.94e-05	9.44e-05	CcSEcCtD
Paroxetine—Decreased appetite—Prednisone—psoriasis	3.93e-05	9.41e-05	CcSEcCtD
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.93e-05	0.000816	CbGpPWpGaD
Paroxetine—Rash—Prednisolone—psoriasis	3.92e-05	9.4e-05	CcSEcCtD
Paroxetine—Dermatitis—Prednisolone—psoriasis	3.92e-05	9.39e-05	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	3.92e-05	9.38e-05	CcSEcCtD
Paroxetine—Fatigue—Prednisone—psoriasis	3.9e-05	9.34e-05	CcSEcCtD
Paroxetine—Headache—Prednisolone—psoriasis	3.9e-05	9.34e-05	CcSEcCtD
Paroxetine—Discomfort—Methotrexate—psoriasis	3.9e-05	9.33e-05	CcSEcCtD
Paroxetine—SLC6A4—Circadian rythm related genes—TP53—psoriasis	3.87e-05	0.000804	CbGpPWpGaD
Paroxetine—Constipation—Prednisone—psoriasis	3.87e-05	9.26e-05	CcSEcCtD
Paroxetine—Vomiting—Hydrocortisone—psoriasis	3.87e-05	9.25e-05	CcSEcCtD
Paroxetine—HTR2A—Signaling by GPCR—CCL20—psoriasis	3.86e-05	0.000801	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—TYK2—psoriasis	3.84e-05	0.000798	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CCL20—psoriasis	3.83e-05	0.000797	CbGpPWpGaD
Paroxetine—Rash—Hydrocortisone—psoriasis	3.83e-05	9.18e-05	CcSEcCtD
Paroxetine—Dermatitis—Hydrocortisone—psoriasis	3.83e-05	9.17e-05	CcSEcCtD
Paroxetine—CHRM3—Signaling by GPCR—CCL20—psoriasis	3.82e-05	0.000794	CbGpPWpGaD
Paroxetine—Confusional state—Methotrexate—psoriasis	3.81e-05	9.12e-05	CcSEcCtD
Paroxetine—Headache—Hydrocortisone—psoriasis	3.81e-05	9.12e-05	CcSEcCtD
Paroxetine—HTR2A—Signaling Pathways—TAGAP—psoriasis	3.8e-05	0.00079	CbGpPWpGaD
Paroxetine—Dizziness—Triamcinolone—psoriasis	3.79e-05	9.06e-05	CcSEcCtD
Paroxetine—CHRM2—Signaling by GPCR—CCL20—psoriasis	3.79e-05	0.000786	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TAGAP—psoriasis	3.78e-05	0.000785	CbGpPWpGaD
Paroxetine—Anaphylactic shock—Methotrexate—psoriasis	3.78e-05	9.05e-05	CcSEcCtD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—psoriasis	3.78e-05	0.000785	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TAGAP—psoriasis	3.77e-05	0.000783	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.76e-05	0.000782	CbGpPWpGaD
Paroxetine—Infection—Methotrexate—psoriasis	3.76e-05	8.99e-05	CcSEcCtD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.76e-05	0.00078	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TAGAP—psoriasis	3.73e-05	0.000775	CbGpPWpGaD
Paroxetine—Feeling abnormal—Prednisone—psoriasis	3.73e-05	8.92e-05	CcSEcCtD
Paroxetine—Asthenia—Dexamethasone—psoriasis	3.73e-05	8.92e-05	CcSEcCtD
Paroxetine—Asthenia—Betamethasone—psoriasis	3.73e-05	8.92e-05	CcSEcCtD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—VEGFA—psoriasis	3.71e-05	0.00077	CbGpPWpGaD
Paroxetine—Nervous system disorder—Methotrexate—psoriasis	3.71e-05	8.87e-05	CcSEcCtD
Paroxetine—Thrombocytopenia—Methotrexate—psoriasis	3.7e-05	8.86e-05	CcSEcCtD
Paroxetine—Gastrointestinal pain—Prednisone—psoriasis	3.7e-05	8.85e-05	CcSEcCtD
Paroxetine—Nausea—Prednisolone—psoriasis	3.7e-05	8.85e-05	CcSEcCtD
Paroxetine—TACR1—GPCR downstream signaling—CXCL8—psoriasis	3.68e-05	0.000765	CbGpPWpGaD
Paroxetine—Pruritus—Betamethasone—psoriasis	3.67e-05	8.8e-05	CcSEcCtD
Paroxetine—Pruritus—Dexamethasone—psoriasis	3.67e-05	8.8e-05	CcSEcCtD
Paroxetine—Skin disorder—Methotrexate—psoriasis	3.67e-05	8.79e-05	CcSEcCtD
Paroxetine—Hyperhidrosis—Methotrexate—psoriasis	3.65e-05	8.75e-05	CcSEcCtD
Paroxetine—Vomiting—Triamcinolone—psoriasis	3.64e-05	8.71e-05	CcSEcCtD
Paroxetine—Nausea—Hydrocortisone—psoriasis	3.61e-05	8.64e-05	CcSEcCtD
Paroxetine—Rash—Triamcinolone—psoriasis	3.61e-05	8.64e-05	CcSEcCtD
Paroxetine—Dermatitis—Triamcinolone—psoriasis	3.61e-05	8.63e-05	CcSEcCtD
Paroxetine—Urticaria—Prednisone—psoriasis	3.59e-05	8.6e-05	CcSEcCtD
Paroxetine—Headache—Triamcinolone—psoriasis	3.59e-05	8.58e-05	CcSEcCtD
Paroxetine—Abdominal pain—Prednisone—psoriasis	3.58e-05	8.56e-05	CcSEcCtD
Paroxetine—Body temperature increased—Prednisone—psoriasis	3.58e-05	8.56e-05	CcSEcCtD
Paroxetine—Diarrhoea—Dexamethasone—psoriasis	3.55e-05	8.51e-05	CcSEcCtD
Paroxetine—Diarrhoea—Betamethasone—psoriasis	3.55e-05	8.51e-05	CcSEcCtD
Paroxetine—SLC6A4—Circadian rythm related genes—IL6—psoriasis	3.54e-05	0.000736	CbGpPWpGaD
Paroxetine—Hypotension—Methotrexate—psoriasis	3.53e-05	8.46e-05	CcSEcCtD
Paroxetine—CHRM1—Circadian rythm related genes—JUN—psoriasis	3.51e-05	0.000729	CbGpPWpGaD
Paroxetine—ABCB1—Allograft Rejection—TNF—psoriasis	3.51e-05	0.000729	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—NDUFA5—psoriasis	3.51e-05	0.000729	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.49e-05	0.000725	CbGpPWpGaD
Paroxetine—Musculoskeletal discomfort—Methotrexate—psoriasis	3.44e-05	8.24e-05	CcSEcCtD
Paroxetine—Dizziness—Betamethasone—psoriasis	3.43e-05	8.22e-05	CcSEcCtD
Paroxetine—Dizziness—Dexamethasone—psoriasis	3.43e-05	8.22e-05	CcSEcCtD
Paroxetine—CYP2C8—Metabolism—CYP2S1—psoriasis	3.42e-05	0.000711	CbGpPWpGaD
Paroxetine—Insomnia—Methotrexate—psoriasis	3.42e-05	8.19e-05	CcSEcCtD
Paroxetine—Nausea—Triamcinolone—psoriasis	3.4e-05	8.14e-05	CcSEcCtD
Paroxetine—Paraesthesia—Methotrexate—psoriasis	3.39e-05	8.13e-05	CcSEcCtD
Paroxetine—Dyspnoea—Methotrexate—psoriasis	3.37e-05	8.07e-05	CcSEcCtD
Paroxetine—Somnolence—Methotrexate—psoriasis	3.36e-05	8.05e-05	CcSEcCtD
Paroxetine—CHRM4—Signaling Pathways—CCL20—psoriasis	3.36e-05	0.000698	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—CXCL8—psoriasis	3.34e-05	0.000695	CbGpPWpGaD
Paroxetine—Hypersensitivity—Prednisone—psoriasis	3.33e-05	7.98e-05	CcSEcCtD
Paroxetine—Dyspepsia—Methotrexate—psoriasis	3.33e-05	7.97e-05	CcSEcCtD
Paroxetine—CYP2D6—Metabolism—NDUFA5—psoriasis	3.31e-05	0.000687	CbGpPWpGaD
Paroxetine—Vomiting—Dexamethasone—psoriasis	3.3e-05	7.91e-05	CcSEcCtD
Paroxetine—Vomiting—Betamethasone—psoriasis	3.3e-05	7.91e-05	CcSEcCtD
Paroxetine—CHRM2—G alpha (i) signalling events—CXCL8—psoriasis	3.29e-05	0.000683	CbGpPWpGaD
Paroxetine—Decreased appetite—Methotrexate—psoriasis	3.29e-05	7.87e-05	CcSEcCtD
Paroxetine—CYP2C9—Metabolism—NDUFA5—psoriasis	3.28e-05	0.000681	CbGpPWpGaD
Paroxetine—Rash—Dexamethasone—psoriasis	3.27e-05	7.84e-05	CcSEcCtD
Paroxetine—Rash—Betamethasone—psoriasis	3.27e-05	7.84e-05	CcSEcCtD
Paroxetine—Dermatitis—Dexamethasone—psoriasis	3.27e-05	7.83e-05	CcSEcCtD
Paroxetine—Dermatitis—Betamethasone—psoriasis	3.27e-05	7.83e-05	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Methotrexate—psoriasis	3.26e-05	7.81e-05	CcSEcCtD
Paroxetine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	3.26e-05	0.000677	CbGpPWpGaD
Paroxetine—Fatigue—Methotrexate—psoriasis	3.26e-05	7.8e-05	CcSEcCtD
Paroxetine—Headache—Betamethasone—psoriasis	3.25e-05	7.79e-05	CcSEcCtD
Paroxetine—Headache—Dexamethasone—psoriasis	3.25e-05	7.79e-05	CcSEcCtD
Paroxetine—Asthenia—Prednisone—psoriasis	3.25e-05	7.77e-05	CcSEcCtD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—TNF—psoriasis	3.24e-05	0.000672	CbGpPWpGaD
Paroxetine—Pain—Methotrexate—psoriasis	3.23e-05	7.74e-05	CcSEcCtD
Paroxetine—CHRM5—Signaling Pathways—CCL20—psoriasis	3.22e-05	0.000668	CbGpPWpGaD
Paroxetine—Pruritus—Prednisone—psoriasis	3.2e-05	7.66e-05	CcSEcCtD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—TNF—psoriasis	3.18e-05	0.00066	CbGpPWpGaD
Paroxetine—Feeling abnormal—Methotrexate—psoriasis	3.12e-05	7.46e-05	CcSEcCtD
Paroxetine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	3.11e-05	0.000646	CbGpPWpGaD
Paroxetine—Diarrhoea—Prednisone—psoriasis	3.09e-05	7.41e-05	CcSEcCtD
Paroxetine—Gastrointestinal pain—Methotrexate—psoriasis	3.09e-05	7.4e-05	CcSEcCtD
Paroxetine—Nausea—Betamethasone—psoriasis	3.09e-05	7.39e-05	CcSEcCtD
Paroxetine—Nausea—Dexamethasone—psoriasis	3.09e-05	7.39e-05	CcSEcCtD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.06e-05	0.000635	CbGpPWpGaD
Paroxetine—Urticaria—Methotrexate—psoriasis	3e-05	7.19e-05	CcSEcCtD
Paroxetine—CHRM4—GPCR ligand binding—CXCL8—psoriasis	2.99e-05	0.000622	CbGpPWpGaD
Paroxetine—Dizziness—Prednisone—psoriasis	2.99e-05	7.16e-05	CcSEcCtD
Paroxetine—Body temperature increased—Methotrexate—psoriasis	2.99e-05	7.15e-05	CcSEcCtD
Paroxetine—Abdominal pain—Methotrexate—psoriasis	2.99e-05	7.15e-05	CcSEcCtD
Paroxetine—ABCB1—Metabolism—CYP2S1—psoriasis	2.98e-05	0.00062	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—LEP—psoriasis	2.97e-05	0.000618	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—APOE—psoriasis	2.97e-05	0.000618	CbGpPWpGaD
Paroxetine—Vomiting—Prednisone—psoriasis	2.88e-05	6.88e-05	CcSEcCtD
Paroxetine—CHRM5—GPCR ligand binding—CXCL8—psoriasis	2.87e-05	0.000595	CbGpPWpGaD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.85e-05	0.000593	CbGpPWpGaD
Paroxetine—Rash—Prednisone—psoriasis	2.85e-05	6.83e-05	CcSEcCtD
Paroxetine—Dermatitis—Prednisone—psoriasis	2.85e-05	6.82e-05	CcSEcCtD
Paroxetine—Headache—Prednisone—psoriasis	2.83e-05	6.78e-05	CcSEcCtD
Paroxetine—CYP2D6—Metabolism—CYP2S1—psoriasis	2.81e-05	0.000584	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP2S1—psoriasis	2.79e-05	0.000579	CbGpPWpGaD
Paroxetine—Hypersensitivity—Methotrexate—psoriasis	2.79e-05	6.67e-05	CcSEcCtD
Paroxetine—TACR1—Signaling Pathways—NFKBIA—psoriasis	2.77e-05	0.000575	CbGpPWpGaD
Paroxetine—Asthenia—Methotrexate—psoriasis	2.71e-05	6.49e-05	CcSEcCtD
Paroxetine—Nausea—Prednisone—psoriasis	2.69e-05	6.43e-05	CcSEcCtD
Paroxetine—Pruritus—Methotrexate—psoriasis	2.67e-05	6.4e-05	CcSEcCtD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.66e-05	0.000553	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.65e-05	0.00055	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.64e-05	0.000549	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.62e-05	0.000543	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—IL6—psoriasis	2.61e-05	0.000543	CbGpPWpGaD
Paroxetine—Diarrhoea—Methotrexate—psoriasis	2.59e-05	6.19e-05	CcSEcCtD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—IL6—psoriasis	2.56e-05	0.000533	CbGpPWpGaD
Paroxetine—Dizziness—Methotrexate—psoriasis	2.5e-05	5.98e-05	CcSEcCtD
Paroxetine—Vomiting—Methotrexate—psoriasis	2.4e-05	5.75e-05	CcSEcCtD
Paroxetine—Rash—Methotrexate—psoriasis	2.38e-05	5.71e-05	CcSEcCtD
Paroxetine—Dermatitis—Methotrexate—psoriasis	2.38e-05	5.7e-05	CcSEcCtD
Paroxetine—Headache—Methotrexate—psoriasis	2.37e-05	5.67e-05	CcSEcCtD
Paroxetine—CHRM1—Circadian rythm related genes—TP53—psoriasis	2.32e-05	0.000481	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.31e-05	0.00048	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CARM1—psoriasis	2.3e-05	0.000477	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCL20—psoriasis	2.28e-05	0.000473	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TYK2—psoriasis	2.27e-05	0.000471	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCL20—psoriasis	2.27e-05	0.000471	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCL20—psoriasis	2.26e-05	0.000469	CbGpPWpGaD
Paroxetine—Nausea—Methotrexate—psoriasis	2.25e-05	5.38e-05	CcSEcCtD
Paroxetine—CHRM2—Signaling Pathways—CCL20—psoriasis	2.24e-05	0.000464	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.23e-05	0.000463	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—IL6—psoriasis	2.12e-05	0.000441	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—CXCL8—psoriasis	2.03e-05	0.000421	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.02e-05	0.00042	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.02e-05	0.00042	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—CXCL8—psoriasis	2.02e-05	0.000419	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—CXCL8—psoriasis	2.01e-05	0.000418	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.01e-05	0.000418	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2e-05	0.000416	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—CXCL8—psoriasis	1.99e-05	0.000414	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CXCL8—psoriasis	1.98e-05	0.00041	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CARM1—psoriasis	1.98e-05	0.00041	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—IL6—psoriasis	1.88e-05	0.00039	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SOCS1—psoriasis	1.85e-05	0.000384	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—JUN—psoriasis	1.84e-05	0.000382	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.79e-05	0.000373	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SOCS1—psoriasis	1.77e-05	0.000368	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—NFKB1—psoriasis	1.77e-05	0.000367	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—TYK2—psoriasis	1.76e-05	0.000366	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.73e-05	0.00036	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—CXCL8—psoriasis	1.69e-05	0.000351	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—TYK2—psoriasis	1.69e-05	0.000351	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CARM1—psoriasis	1.67e-05	0.000347	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—CXCL8—psoriasis	1.62e-05	0.000336	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—VEGFA—psoriasis	1.6e-05	0.000333	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—STAT3—psoriasis	1.59e-05	0.00033	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.56e-05	0.000325	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—CXCL8—psoriasis	1.54e-05	0.000319	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.53e-05	0.000317	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—CXCL8—psoriasis	1.47e-05	0.000305	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.46e-05	0.000303	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CARM1—psoriasis	1.46e-05	0.000303	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CAT—psoriasis	1.41e-05	0.000293	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CARM1—psoriasis	1.37e-05	0.000285	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—APOE—psoriasis	1.37e-05	0.000284	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—LEP—psoriasis	1.37e-05	0.000284	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CARM1—psoriasis	1.36e-05	0.000283	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—APOE—psoriasis	1.31e-05	0.000272	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—LEP—psoriasis	1.31e-05	0.000272	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.27e-05	0.000264	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NFKBIA—psoriasis	1.27e-05	0.000264	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SOCS1—psoriasis	1.25e-05	0.00026	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SOCS1—psoriasis	1.25e-05	0.000259	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SOCS1—psoriasis	1.24e-05	0.000258	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SOCS1—psoriasis	1.23e-05	0.000256	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NFKBIA—psoriasis	1.22e-05	0.000253	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CAT—psoriasis	1.21e-05	0.000252	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TP53—psoriasis	1.21e-05	0.000252	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—TYK2—psoriasis	1.2e-05	0.000248	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—TYK2—psoriasis	1.19e-05	0.000247	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—TYK2—psoriasis	1.19e-05	0.000246	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—TYK2—psoriasis	1.17e-05	0.000244	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—CXCL8—psoriasis	1.15e-05	0.000238	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—CXCL8—psoriasis	1.14e-05	0.000237	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—CXCL8—psoriasis	1.14e-05	0.000236	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—CXCL8—psoriasis	1.13e-05	0.000234	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—IL6—psoriasis	1.11e-05	0.000231	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—APOE—psoriasis	1.1e-05	0.000228	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TYK2—psoriasis	1.04e-05	0.000216	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CXCL8—psoriasis	1.04e-05	0.000216	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CXCL8—psoriasis	1.04e-05	0.000215	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CXCL8—psoriasis	1.03e-05	0.000214	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CAT—psoriasis	1.03e-05	0.000214	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CXCL8—psoriasis	1.02e-05	0.000212	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TYK2—psoriasis	9.98e-06	0.000207	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PPARG—psoriasis	9.56e-06	0.000199	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—APOE—psoriasis	9.44e-06	0.000196	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—LEP—psoriasis	9.25e-06	0.000192	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—APOE—psoriasis	9.25e-06	0.000192	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—LEP—psoriasis	9.2e-06	0.000191	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—APOE—psoriasis	9.2e-06	0.000191	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—LEP—psoriasis	9.18e-06	0.000191	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—APOE—psoriasis	9.18e-06	0.000191	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—APOE—psoriasis	9.09e-06	0.000189	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—LEP—psoriasis	9.09e-06	0.000189	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CXCL8—psoriasis	9.07e-06	0.000188	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CAT—psoriasis	8.96e-06	0.000186	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CXCL8—psoriasis	8.69e-06	0.00018	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—IL6—psoriasis	8.63e-06	0.000179	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NFKBIA—psoriasis	8.62e-06	0.000179	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NFKBIA—psoriasis	8.58e-06	0.000178	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NFKBIA—psoriasis	8.55e-06	0.000178	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NFKBIA—psoriasis	8.47e-06	0.000176	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CAT—psoriasis	8.44e-06	0.000175	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—JUN—psoriasis	8.43e-06	0.000175	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CAT—psoriasis	8.37e-06	0.000174	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—IL6—psoriasis	8.26e-06	0.000172	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PPARG—psoriasis	8.22e-06	0.000171	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NFKB1—psoriasis	8.12e-06	0.000169	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—JUN—psoriasis	8.08e-06	0.000168	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—APOE—psoriasis	7.99e-06	0.000166	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NFKB1—psoriasis	7.77e-06	0.000161	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VEGFA—psoriasis	7.37e-06	0.000153	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—STAT3—psoriasis	7.3e-06	0.000152	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TYK2—psoriasis	7.06e-06	0.000147	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VEGFA—psoriasis	7.06e-06	0.000147	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TYK2—psoriasis	7.03e-06	0.000146	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TYK2—psoriasis	7e-06	0.000145	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—STAT3—psoriasis	6.99e-06	0.000145	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—APOE—psoriasis	6.96e-06	0.000145	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PPARG—psoriasis	6.96e-06	0.000145	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TYK2—psoriasis	6.94e-06	0.000144	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—APOE—psoriasis	6.56e-06	0.000136	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—APOE—psoriasis	6.5e-06	0.000135	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CXCL8—psoriasis	6.15e-06	0.000128	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CXCL8—psoriasis	6.12e-06	0.000127	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CXCL8—psoriasis	6.1e-06	0.000127	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PPARG—psoriasis	6.06e-06	0.000126	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CXCL8—psoriasis	6.04e-06	0.000125	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL6—psoriasis	5.85e-06	0.000121	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL6—psoriasis	5.82e-06	0.000121	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL6—psoriasis	5.8e-06	0.00012	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL6—psoriasis	5.74e-06	0.000119	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—JUN—psoriasis	5.72e-06	0.000119	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PPARG—psoriasis	5.72e-06	0.000119	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—JUN—psoriasis	5.69e-06	0.000118	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—JUN—psoriasis	5.67e-06	0.000118	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PPARG—psoriasis	5.67e-06	0.000118	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—JUN—psoriasis	5.61e-06	0.000117	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—psoriasis	5.57e-06	0.000116	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NFKB1—psoriasis	5.5e-06	0.000114	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NFKB1—psoriasis	5.47e-06	0.000114	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NFKB1—psoriasis	5.46e-06	0.000113	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NFKB1—psoriasis	5.4e-06	0.000112	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—psoriasis	5.33e-06	0.000111	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL6—psoriasis	5.1e-06	0.000106	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VEGFA—psoriasis	4.99e-06	0.000104	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VEGFA—psoriasis	4.97e-06	0.000103	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VEGFA—psoriasis	4.95e-06	0.000103	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—STAT3—psoriasis	4.95e-06	0.000103	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—STAT3—psoriasis	4.92e-06	0.000102	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VEGFA—psoriasis	4.9e-06	0.000102	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—STAT3—psoriasis	4.9e-06	0.000102	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL6—psoriasis	4.88e-06	0.000101	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—STAT3—psoriasis	4.86e-06	0.000101	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—psoriasis	3.77e-06	7.84e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—psoriasis	3.75e-06	7.8e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—psoriasis	3.74e-06	7.77e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—psoriasis	3.71e-06	7.7e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6—psoriasis	3.45e-06	7.18e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6—psoriasis	3.44e-06	7.14e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6—psoriasis	3.43e-06	7.11e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6—psoriasis	3.39e-06	7.05e-05	CbGpPWpGaD
